Clinical Trial Update: Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab

View source ↗

Summary

An update on neurocognitive changes observed in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Cantonal Hospital of St. Gallen | Conditions: Multiple Sclerosis, Cognitive Impairment | Status: UNKNOWN